David P. Ryan - Concepedia

Author

David P. Ryan

Also Known As

D P Ryan, D Ryan, D. P. Ryan, D. Ryan, D.P Ryan, D.P. Ryan, DAVID RYAN, David Lawrence Ryan, David P Ryan, David P. Ryan

937

Publications

35K

Citations

H-Index

218

Concepts

All Affiliations

Massachusetts General Hospital Harvard University Dana-Farber Cancer Institute Brigham and Women's Hospital Dana-Farber Brigham Cancer Center

About

David P. Ryan is an author at Massachusetts General Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	26	40	4.2K
2	Education	7	7	196
3	Engineering	3	3	109
4	Arts	2	2	51
5	Language Studies	1	1	11

David P. Ryan

294

Publications

30.4K

Citations

H-Index

Page 1

	Year	Citations
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Christopher G. Willett, Yves Boucher, Emmanuelle di Tomaso, Nature Medicine AngiogenesisMedicineHuman Rectal CancerImmunologyPathology	2004	1.9K
Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer Cristina R. Ferrone, Giovanni Marchegiani, Theodore S. Hong, Annals of Surgery	2014	823
Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial Jennifer S. Temel, Joseph A. Greer, Areej El‐Jawahri, Journal of Clinical Oncology Palliative CareQuality Of LifeRandomized Clinical TrialIntervention PatientsGi Cancer	2017	805
Frequent Mutation of Isocitrate Dehydrogenase<i>(IDH)1</i>and<i>IDH2</i>in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping Darrell R. Borger, Kenneth K. Tanabe, Kenneth C. Fan, The Oncologist	2011	702
Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors Matthew H. Kulke, Heinz‐Josef Lenz, Neal J. Meropol, Journal of Clinical Oncology	2008	618
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study Michael S. Lee, Baek‐Yeol Ryoo, Chih‐Hung Hsu, The Lancet Oncology Phase 1BHepatologyMedicineImmunologyPathology	2020	555
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma Janet E. Murphy, Jennifer Y. Wo, David P. Ryan, JAMA Oncology	2018	531
Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma Lipika Goyal, Supriya K. Saha, Leah Y. Liu, Cancer Discovery	2016	527
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers Aparna R. Parikh, Ignaty Leshchiner, Liudmila Elagina, Nature Medicine Gastrointestinal OncologyTumor HeterogeneityMedicineCancer DetectionGastrointestinal Cancers	2019	513
Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors Matthew H. Kulke, Keith Stuart, Peter C. Enzinger, Journal of Clinical Oncology	2006	512

Page 1